All of Us study finds thousands of new genetic variants affecting drug responses

A study drawing on nearly 100,000 participants in the National Institutes of Health’s All of Us research program has identified thousands of previously uncatalogued genetic variants in genes governing how the body processes prescription drugs, according to STAT News.

The research, reported November 11, examined a cohort recruited specifically for its demographic diversity, a design choice that distinguishes it from earlier pharmacogenomic studies drawn largely from populations of European ancestry. STAT News reports that this broader sampling surfaced variants in drug-metabolism genes that had not previously appeared in the scientific literature, variants concentrated in groups historically underrepresented in genomic research.

Pharmacogenomic variants of this kind affect how individuals metabolize medications, influencing whether a standard dose proves effective, ineffective, or harmful. The summary provided indicates that the scale of new findings numbers in the thousands, though the specific drug classes and genes most affected were not detailed in the available material.

The All of Us program, launched by the National Institutes of Health, aims to build a research resource reflecting the genetic and demographic range of the American population, a stated corrective to gaps left by prior genomic studies. STAT News’s account situates this latest result within that ongoing effort, framing the expanded variant catalog as a step toward prescribing practices informed by a fuller picture of human genetic variation. Further detail on clinical application was not specified in the reporting available to this desk.